rel
bioavail
nicotin
nasal
spray
assess
smoker
suffer
common
cold
rhiniti
accord
gener
accept
criteria
patient
given
singl
dose
mg
nicotin
nasal
spray
without
concurr
administr
nasal
vasoconstrictor
decongest
xylometazolin
randomis
order
control
session
measur
made
diseasefre
state
appli
strict
bioequival
criteria
found
common
coldrhin
slightli
reduc
bioavail
nicotin
rate
extent
geometr
mean
ratio
crnax
auc
tma
x
respect
nasal
vasoconstrictor
xylometazolin
normalis
extent
bioavail
nicotin
prolong
time
absorpt
almost
twice
measur
diseasefre
state
increas
tma
x
ratio
result
suggest
minor
proport
peopl
stop
smoke
help
nicotin
nasal
spray
may
experi
minor
reduct
effect
spray
common
coldrhin
howev
nicotin
selftitr
behaviour
found
smoke
cessat
product
except
nicotin
patch
automat
lead
adjust
dosag
achiev
desir
effect
nasal
caviti
line
larg
area
well
vascular
mucosa
permit
rapid
absorpt
number
drug
intranas
administr
explor
altern
rout
drug
administr
develop
nicotin
nasal
spray
primarili
stem
experiment
work
show
rapid
absorpt
nicotin
nasal
snuff
fact
plasma
nicotin
profil
use
nasal
spray
closer
seen
smoke
form
nicotin
replac
obviou
reason
diseas
affect
nasal
mucosa
eg
inflammatori
diseas
nasal
obstruct
discharg
may
interfer
absorpt
nicotin
administ
nose
complic
factor
possibl
treatment
symptom
local
administ
vasoconstrictor
situat
face
mani
patient
use
nicotin
nasal
spray
import
determin
extent
rhiniti
concurr
administr
nasal
vasoconstrictor
decongest
might
affect
bioavail
intranas
nicotin
studi
open
threeway
crossov
design
bioavail
nicotin
nasal
spray
assess
without
concurr
treatment
vasoconstrictor
confirm
attack
rhiniti
result
compar
diseasefre
state
sequenc
rhiniti
session
randomis
session
subject
diseasefre
perform
soon
possibl
episod
rhiniti
fifteen
healthi
smoker
year
age
particip
studi
histori
alcohol
abus
drug
depend
subject
abstain
nicotin
least
h
prior
drug
administr
throughout
entir
experiment
session
studi
approv
ethic
committe
univers
lund
conduct
accord
helsinki
declar
subject
gave
written
consent
prior
start
studi
nicotin
nasal
spray
nicorett
rag
nasal
spray
contain
vasoconstrictor
xylometazolin
otrivin
e
mg
use
spray
deliv
solut
contain
mg
nicotin
mg
xylometazolin
respect
recommend
dose
nicotin
nasal
spray
one
spray
nasal
caviti
e
mg
one
two
dose
per
hour
exceed
dose
per
hour
ensur
plasma
nicotin
level
limit
quantif
long
enough
time
period
allow
adequ
pharmacokinet
calcul
two
dose
mg
given
min
dose
administr
nicotin
decongest
spray
bottl
prime
spray
five
time
air
order
demonstr
proper
function
devic
avoid
nicotin
contamin
done
separ
room
someon
involv
take
blood
sampl
one
spray
mg
nicotin
nicotin
solut
spray
nasal
caviti
one
investig
procedur
repeat
min
quiet
rest
nozzl
spray
bottl
insert
parallel
septum
front
edg
insid
nasal
vestibul
nozzl
point
frontal
wall
nasal
floor
subject
blow
nose
first
dose
sit
upright
treatment
vasoconstrictor
xylometazolin
administ
min
prior
nicotin
nasal
spray
one
spray
mg
xylometazolin
given
nostril
common
coldrhin
confirm
fulfil
criteria
andor
criterion
describ
total
score
point
follow
symptom
characterist
common
cold
sneez
headach
malais
chilli
nasal
discharg
nasal
obstruct
sore
throat
cough
grade
none
mild
moder
sever
subject
report
respons
activ
question
accord
checklist
oral
contracept
allow
restrict
use
otc
product
except
nasal
decongest
neither
studi
prescrib
medic
drug
investig
use
concomitantli
studi
drug
venou
blood
sampl
ml
collect
antecubit
vein
sodium
heparinis
glass
tube
follow
time
directli
prior
administr
min
h
administr
first
dose
blood
sampl
cool
centrifug
within
min
plasma
transfer
cryotub
kept
frozen
pend
analysi
nicotin
determin
capillari
ga
chromatographi
singl
step
liquidliquid
extract
plasma
sampl
detect
mean
nitrogen
sensit
detector
high
select
sensit
precis
method
ng
ml
level
nicotin
better
cv
ng
ml
better
cv
level
quantif
ng
administr
follow
calcul
perform
aucin
r
calcul
auc
denot
last
time
point
linear
trapezoid
method
plu
area
use
equat
c
tt
kel
elimin
rate
constant
kel
obtain
linear
regress
plasma
concentr
valu
termin
slope
logarithm
plasma
concentrationtim
curv
maximum
nicotin
plasma
concentr
time
peak
plasma
concentr
determin
observ
plasma
concentrationtim
curv
hgcin
f
cma
x
correct
baselin
nicotin
concentr
co
shown
impress
subject
himherself
common
cold
develop
fewer
symptom
point
presenc
increas
nasal
discharg
rhinorrhoea
swell
grade
assess
anterior
rhinoscopi
degre
swell
nasal
discharg
redden
estim
use
scale
point
score
includ
total
symptom
score
variabl
auc
cma
analys
use
anova
least
squar
mean
natur
logarithm
transform
variabl
tma
x
analys
use
wilcoxon
test
rank
transform
data
convent
methodolog
bioequival
analysi
use
evalu
effect
common
coldrhin
xylometazolin
pharmacokinet
intranas
administ
nicotin
follow
comparison
made
testrefer
common
coldrhin
vs
normal
rhiniti
xylometazolin
vs
normal
bioequival
ie
lack
interact
assess
rate
c
ti
extent
aucinf
accept
confid
interv
error
anova
log
transform
aucinf
cma
xand
tmaxratio
testrefer
contain
within
interv
aucinf
cmax
tmax
time
h
fig
mean
sem
plasma
nicotin
concentr
fifteen
subject
infecti
rhiniti
concomit
use
topic
decongest
normal
health
follow
intranas
spray
mg
nicotin
clariti
plasma
concentrationtim
curv
rhiniti
without
concomit
xylometazolin
similar
rhiniti
xylometazolin
omit
mean
uncorrect
plasma
nicotin
level
similar
diseasefre
state
rhiniti
rhiniti
plu
xylometazolin
mean
plasma
level
shown
fig
mean
sd
peak
plasma
concentr
cmax
correct
baselin
nicotin
concentr
rhiniti
ng
compar
ng
ml
diseasefre
state
cma
x
rig
ml
found
rhiniti
plu
concomit
use
decongest
tabl
time
peak
concentr
tmax
invers
relat
accordingli
tma
x
occur
later
rhiniti
h
diseasefre
state
h
tma
x
prolong
h
rhiniti
treat
xylometazolin
area
plasma
concentrationtim
curv
extrapol
infin
aucinf
correct
baselin
nicotin
concentr
rhiniti
rhiniti
xylometazolin
estim
ng
h
ngml
jh
respect
agcin
f
diseasefre
state
ng
h
tabl
mean
elimin
halflif
estim
diseasefre
state
h
rhiniti
without
decongest
h
mean
bioavail
intranas
nicotin
similar
common
coldrhin
diseasefre
state
geometr
mean
ratio
aucrhin
aucnorrn
ci
peak
plasma
concentr
ratio
ratio
time
peak
concentr
latter
significantli
longer
common
coldrhin
compar
diseasefre
state
p
confid
interv
outsid
bioequival
rang
aucin
f
cm
tmax
common
coldrhin
compar
diseasefre
state
consid
equival
neither
term
rate
extent
nicotin
absorpt
xylometazolin
given
rain
prior
nicotin
nasal
spray
common
coldrhin
area
nicotin
plasma
concentrationtim
curv
somewhat
larger
nicotin
spray
use
normal
health
geometr
mean
aucratio
outsid
upper
limit
equival
rang
extent
bioavail
indic
least
much
nicotin
avail
system
circul
common
coldrhin
pretreat
decongest
diseasefre
state
significantli
slower
nicotin
absorpt
rhiniti
treat
vasoconstrictor
decongest
compar
diseasefre
state
indic
lower
cma
x
p
later
tma
x
p
appli
convent
bioequival
criteria
two
experiment
situat
could
consid
equival
geometr
mean
ratio
cma
tma
x
respect
commonli
report
advers
event
sneez
irrit
throat
headach
event
rate
mild
subject
except
one
report
headach
rate
moder
latter
report
common
coldrhin
session
could
discrimin
symptom
diseas
nasal
administr
nicotin
recent
found
pratic
use
aid
smoke
withdraw
programm
diseas
affect
nasal
mucosa
eg
inflamm
nasal
obstruct
nasal
discharg
may
interfer
absorpt
intranas
administ
nicotin
might
necessari
adjust
dose
cold
present
studi
appli
methodolog
bioequival
test
rather
test
nullhypothesi
equal
diseas
nondiseas
state
demonstr
whether
pharmacokinet
intranas
administ
nicotin
affect
clinic
relev
extent
rhiniti
topic
decongest
could
conclud
classic
hypothesi
test
differ
two
situat
test
instead
necessari
show
rate
extent
absorpt
intranas
nicotin
diseas
nondiseas
state
equival
ie
ratio
cma
x
auc
confid
interv
contain
within
clinic
accept
rang
would
ensur
consum
risk
would
exceed
recent
studi
shown
absorpt
permeabl
nasal
mucosa
decreas
inflamm
eg
activ
season
allerg
rhiniti
end
pollen
season
well
common
cold
coronaviru
induc
rhiniti
possibl
explan
reduc
absorpt
exud
bulk
plasma
subepitheli
tissu
airway
lumen
complic
factor
drug
given
topic
nose
common
cold
concomit
treatment
local
administ
vasoconstrictor
rhiniti
previous
demonstr
increas
ml
min
tissu
nasal
mucos
blood
flow
compar
diseasefre
state
topic
vasoconstrictor
given
reduct
ml
rain
tissu
increas
blood
flow
thu
nasal
mucos
blood
flow
common
cold
treatment
local
vasoconstrictor
approxim
lower
diseasefre
state
present
studi
demonstr
rhiniti
reduc
mean
peak
plasma
nicotin
concentr
significantli
prolong
time
peak
concentr
intranas
administ
nicotin
pretreat
xylometazolin
prolong
absorpt
time
comparison
untreat
rhiniti
without
affect
peak
plasma
nicotin
level
extent
absorpt
larg
unaffect
data
indic
slow
absorpt
process
reduc
rate
nicotin
absorpt
common
cold
probabl
result
slower
access
nicotin
subepitheli
capillari
well
vascularis
nasal
mucosa
reduct
found
pretreat
vasoconstrictor
result
decreas
nasal
mucos
blood
flow
bioequival
rang
adopt
present
studi
extent
bioavail
maximum
plasma
concentr
time
reach
maximum
concentr
gener
appropri
bioequival
rang
chosen
clinic
ground
thu
drug
like
nicotin
broad
therapeut
rang
selftitr
behaviour
smoker
wider
confid
limit
consid
result
suggest
minor
proport
quit
smoke
help
nicotin
nasal
spray
may
experi
minor
reduct
effect
common
coldrhin
howev
nicotin
selftitr
behaviour
found
smoke
cessat
product
except
nicotin
patch
automat
lead
adjust
dosag
achiev
desir
effect
